ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Update

ADMA Biologics, Inc. (NASDAQ:ADMA) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 13,620,000 shares, a growth of 11.8% from the December 15th total of 12,180,000 shares. Based on an average trading volume of 3,500,000 shares, the days-to-cover ratio is presently 3.9 days.

Analyst Upgrades and Downgrades

ADMA has been the topic of several research reports. HC Wainwright upped their price target on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th. Finally, Raymond James increased their target price on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research note on Friday, November 8th.

Insider Activity

In other news, CFO Brad L. Tade sold 15,000 shares of the company’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares of the company’s stock, valued at $4,218,007.95. This represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 3.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ADMA Biologics

Several large investors have recently modified their holdings of the business. State Street Corp increased its holdings in shares of ADMA Biologics by 61.4% in the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock worth $259,970,000 after acquiring an additional 4,945,063 shares in the last quarter. D. E. Shaw & Co. Inc. increased its holdings in shares of ADMA Biologics by 26.8% in the second quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock worth $76,298,000 after acquiring an additional 1,442,799 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of ADMA Biologics by 2.6% in the third quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company’s stock worth $107,606,000 after acquiring an additional 137,989 shares in the last quarter. Perpetual Ltd bought a new stake in shares of ADMA Biologics in the fourth quarter worth about $62,300,000. Finally, Assenagon Asset Management S.A. increased its holdings in shares of ADMA Biologics by 2.7% in the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock worth $69,454,000 after acquiring an additional 92,281 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Trading Down 3.7 %

NASDAQ:ADMA opened at $16.02 on Friday. ADMA Biologics has a 1-year low of $4.86 and a 1-year high of $23.64. The business’s 50-day moving average price is $19.04 and its two-hundred day moving average price is $17.25. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $3.79 billion, a price-to-earnings ratio of 57.21 and a beta of 0.76.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The firm had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. During the same quarter in the prior year, the firm posted $0.01 earnings per share. On average, equities analysts expect that ADMA Biologics will post 0.52 earnings per share for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.